trial

Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients

NCTId NCT02109562
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 354 (actual)
Sponsored by Indivior Inc.
Primary completion 2014-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
354 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2014-04
Primary completion
2014-11
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
RBP-7000Risperidone

Sponsors

Indivior Inc.Lead Sponsor

Investigators

1
Global Clinical Developoment ManagerStudy Director

Sites

32 total
Little Rock, United StatesSpringdale, United StatesCerritos, United StatesEscondido, United StatesGlendale, United StatesLong Beach, United StatesLong Beach, United StatesOakland, United StatesOceanside, United StatesPico Rivera, United StatesSan Diego, United StatesFort Lauderdale, United States

Linked catalysts

1
Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of R — primary completion2014-11

Facts & assertions

4 sourced
Enrollment
354
Phase
PHASE3
Primary Completion Date
2014-11
Status
COMPLETED
relationships
The graph out of here
drug
RBP-7000
drug
Risperidone
drug
lead_sponsor
Indivior Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Global Clinical Developoment Manager
person